Amarin Bounces Back; Up 4.5%

Shares of biotechnology company Amarin AMRN are bouncing back on Tuesday, rising 4.47% to $14.25. The stock has been hit hard over the last month, falling almost 23%. Over the last 52-weeks, however, Amarin shares are up 455%. Amarin Corporation plc (Amarin) is a clinical-stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease. The Company's development programs capitalize in the field of lipid science and the therapeutic benefits of essential fatty acids in cardiovascular disease.